U.S. Judge Denies Bayer's Bid for Injunction Against Johnson & Johnson's Alleged Misstatements Regarding Prostate Cancer Medication
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 17 2026
0mins
Source: moomoo
Court Ruling: A U.S. judge has denied Bayer's request for an injunction to block Johnson & Johnson's alleged false statements regarding a prostate cancer drug.
Implications for Bayer: The ruling allows Johnson & Johnson to continue its marketing and sales of the drug without interruption from Bayer's claims.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy JNJ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on JNJ
Wall Street analysts forecast JNJ stock price to fall
20 Analyst Rating
13 Buy
7 Hold
0 Sell
Moderate Buy
Current: 235.180
Low
190.00
Averages
218.50
High
240.00
Current: 235.180
Low
190.00
Averages
218.50
High
240.00
About JNJ
Johnson & Johnson and its subsidiaries are engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The Company’s segments include Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, cardiovascular and metabolism. Its products include REMICADE (infliximab), SIMPONI (golimumab), SIMPONI ARIA (golimumab), STELARA (ustekinumab), TREMFYA (guselkumab), EDURANT (rilpivirine), and INVEGA SUSTENNA/XEPLION (paliperidone palmitate). The MedTech segment includes a portfolio of products used in cardiovascular, orthopedics, surgery, and vision categories. The Cardiovascular portfolio includes electrophysiology products to treat heart rhythm disorders and circulatory restoration products (Shockwave) for the treatment of calcified coronary artery disease (CAD) and peripheral artery disease (PAD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Johnson & Johnson Invests Over $1 Billion to Expand U.S. Manufacturing
- Major Investment: Johnson & Johnson announces an investment exceeding $1 billion to expand its Vision operations in Jacksonville, Florida, aimed at enhancing production capacity for ACUVUE contact lenses to meet growing market demand.
- Facility Construction: The investment includes the construction of a state-of-the-art distribution facility and the introduction of advanced manufacturing and packaging technologies, expected to significantly increase capacity and ensure high-quality eye health products for over 40 million patients.
- Long-term Commitment: This expansion is part of Johnson & Johnson's previously disclosed $55 billion commitment to U.S. manufacturing, R&D, and technology investments, further supporting its 3,500 employees in Florida and contributing to a $6 billion annual economic impact.
- Future Outlook: Construction of the new distribution facility is already underway, with full operational readiness targeted for 2028, and this investment is expected to solidify Johnson & Johnson's leadership in the U.S. vision-care market while supporting long-term growth in Jacksonville.
See More
Market Volatility and Portfolio Performance Overview
- Market Volatility Overview: The S&P 500 experienced significant volatility over the past three weeks, recording its worst session in eight months on June 5, just after reaching record highs, indicating shifts in market sentiment and investor uncertainty.
- Portfolio Performance: Among 34 stocks, 19 have risen since the May meeting, with Arm's stock soaring 38.2% driven by strong AI demand and the release of a new Nvidia chip, highlighting the potential for a rebound in tech stocks.
- Bank Stocks Recovery: Wells Fargo's shares increased by 13.9%, reflecting the financial sector's status as the best-performing group in the S&P 500, although it remains down nearly 7% year-to-date, suggesting a cautious recovery amid potential earnings volatility.
- Underperforming Stocks: Amazon's stock fell 10.8%, primarily due to concerns over AI investments, despite securing a $17.5 billion loan for AI development, raising questions about its future financial health and investor confidence.
See More
Citadel Advisors Increases Stake in Intuitive Surgical Amid Market Challenges
- AI Stock Reduction: Citadel Advisors sold 2.9 million shares of Nvidia and 6 million shares of Amazon in Q1, although both remain among its largest holdings, indicating a strategic shift to reallocate capital into more attractive investment opportunities.
- Healthcare Stake Increase: The firm increased its stake in Intuitive Surgical by 30.3% during the first quarter, reflecting confidence in the company's long-term prospects despite facing multiple challenges from competition, lower-margin products, and tariffs.
- Intensifying Market Competition: Intuitive Surgical is encountering increased competition in the robotic-assisted surgery market from Medtronic and Johnson & Johnson; however, the company maintains a significant lead due to its 26 years of market experience and extensive installed base.
- Profitability Outlook: Despite Intuitive Surgical's high valuation with a forward P/E ratio of 39.7, its revenue and earnings growth outpace peers, and its strong competitive edge in the medical device sector justifies this premium.
See More
Citadel Advisors Increases Stake in Intuitive Surgical Amid Challenges
- Increased Stake: Citadel Advisors raised its stake in Intuitive Surgical by 30.3% in Q1, demonstrating confidence in the company's long-term growth potential despite facing challenges such as increased competition and tariffs.
- Market Competition: Intuitive Surgical is encountering competitive pressure in the robotic-assisted surgery market from companies like Medtronic and Johnson & Johnson; however, its 26 years of market experience and strong customer base help maintain its leading position.
- Financial Pressures: Despite relatively strong financial results, Intuitive Surgical's stock has dropped 20% over the past 12 months due to declining product margins and tariff impacts, raising investor concerns about its future performance.
- Long-Term Outlook: Intuitive Surgical is exploring ways to leverage artificial intelligence to enhance its device capabilities, and despite current challenges, its vast market potential and high switching costs provide a solid foundation for future growth.
See More
Trump Announces US-Iran Deal, Market Rallies
- Market Rally: Following Trump's announcement of a US-Iran peace deal, the S&P 500 rose by 1.85%, marking its best performance since April 8, indicating a positive market reaction to reduced geopolitical risks.
- Tech Sector Surge: The Nasdaq jumped over 3%, achieving its best session since March 31, reflecting renewed investor confidence in tech stocks, which may drive future investment inflows.
- Pharma Stock Pressure: Pharmaceutical stocks face downward pressure after the Centers for Medicare and Medicaid Services proposed new drug price negotiations, with analysts warning of potential risks for companies like Johnson & Johnson and Bristol Myers, impacting their short-term performance.
- Salesforce Acquisition: Salesforce announced its acquisition of customer service platform Fin for $3.6 billion, expected to close in Q4 of fiscal year 2027, aimed at enhancing its AI customer service capabilities, although its stock failed to maintain gains during the market rally, highlighting uncertainty about AI's long-term impact.
See More
CMS Proposes Permanent Drug Price Negotiations for Medicare
- Negotiation Risk: The CMS proposed rule unveiled on June 12 aims to make Medicare drug price negotiations permanent, set to take effect in 2029, which has led to a decline in stock prices for drugmakers like Merck (MRK), Johnson & Johnson (JNJ), and Bristol Myers Squibb (BMY) due to increased negotiation risk.
- Market Impact: RBC analyst Trung Huynh warned that this development places significant pressure on pharmaceutical companies, particularly those relying on drugs like Darzalex, Opdivo, and Keytruda to extend their product lifecycles, potentially affecting their future revenue forecasts.
- Biosimilar Protection: In contrast, Regeneron's Eylea HD remains protected from this negotiation risk due to the existence of bona fide marketed biosimilars, exempting its entire product bundle from the proposed rule, which may help maintain its competitive edge in the market.
- Clinical Trial Results: Johnson & Johnson's multiple myeloma drug Talvey has shown a mortality risk reduction of up to 53% in late-stage trials, which may alleviate some investor concerns regarding the implications of the CMS proposal.
See More
Johnson & Johnson Invests Over $1 Billion to Expand U.S. Manufacturing
- Major Investment: Johnson & Johnson announces an investment exceeding $1 billion to expand its Vision operations in Jacksonville, Florida, aimed at enhancing production capacity for ACUVUE contact lenses to meet growing market demand.
- Facility Construction: The investment includes the construction of a state-of-the-art distribution facility and the introduction of advanced manufacturing and packaging technologies, expected to significantly increase capacity and ensure high-quality eye health products for over 40 million patients.
- Long-term Commitment: This expansion is part of Johnson & Johnson's previously disclosed $55 billion commitment to U.S. manufacturing, R&D, and technology investments, further supporting its 3,500 employees in Florida and contributing to a $6 billion annual economic impact.
- Future Outlook: Construction of the new distribution facility is already underway, with full operational readiness targeted for 2028, and this investment is expected to solidify Johnson & Johnson's leadership in the U.S. vision-care market while supporting long-term growth in Jacksonville.
See More
Market Volatility and Portfolio Performance Overview
- Market Volatility Overview: The S&P 500 experienced significant volatility over the past three weeks, recording its worst session in eight months on June 5, just after reaching record highs, indicating shifts in market sentiment and investor uncertainty.
- Portfolio Performance: Among 34 stocks, 19 have risen since the May meeting, with Arm's stock soaring 38.2% driven by strong AI demand and the release of a new Nvidia chip, highlighting the potential for a rebound in tech stocks.
- Bank Stocks Recovery: Wells Fargo's shares increased by 13.9%, reflecting the financial sector's status as the best-performing group in the S&P 500, although it remains down nearly 7% year-to-date, suggesting a cautious recovery amid potential earnings volatility.
- Underperforming Stocks: Amazon's stock fell 10.8%, primarily due to concerns over AI investments, despite securing a $17.5 billion loan for AI development, raising questions about its future financial health and investor confidence.
See More
Citadel Advisors Increases Stake in Intuitive Surgical Amid Market Challenges
- AI Stock Reduction: Citadel Advisors sold 2.9 million shares of Nvidia and 6 million shares of Amazon in Q1, although both remain among its largest holdings, indicating a strategic shift to reallocate capital into more attractive investment opportunities.
- Healthcare Stake Increase: The firm increased its stake in Intuitive Surgical by 30.3% during the first quarter, reflecting confidence in the company's long-term prospects despite facing multiple challenges from competition, lower-margin products, and tariffs.
- Intensifying Market Competition: Intuitive Surgical is encountering increased competition in the robotic-assisted surgery market from Medtronic and Johnson & Johnson; however, the company maintains a significant lead due to its 26 years of market experience and extensive installed base.
- Profitability Outlook: Despite Intuitive Surgical's high valuation with a forward P/E ratio of 39.7, its revenue and earnings growth outpace peers, and its strong competitive edge in the medical device sector justifies this premium.
See More
Citadel Advisors Increases Stake in Intuitive Surgical Amid Challenges
- Increased Stake: Citadel Advisors raised its stake in Intuitive Surgical by 30.3% in Q1, demonstrating confidence in the company's long-term growth potential despite facing challenges such as increased competition and tariffs.
- Market Competition: Intuitive Surgical is encountering competitive pressure in the robotic-assisted surgery market from companies like Medtronic and Johnson & Johnson; however, its 26 years of market experience and strong customer base help maintain its leading position.
- Financial Pressures: Despite relatively strong financial results, Intuitive Surgical's stock has dropped 20% over the past 12 months due to declining product margins and tariff impacts, raising investor concerns about its future performance.
- Long-Term Outlook: Intuitive Surgical is exploring ways to leverage artificial intelligence to enhance its device capabilities, and despite current challenges, its vast market potential and high switching costs provide a solid foundation for future growth.
See More
Trump Announces US-Iran Deal, Market Rallies
- Market Rally: Following Trump's announcement of a US-Iran peace deal, the S&P 500 rose by 1.85%, marking its best performance since April 8, indicating a positive market reaction to reduced geopolitical risks.
- Tech Sector Surge: The Nasdaq jumped over 3%, achieving its best session since March 31, reflecting renewed investor confidence in tech stocks, which may drive future investment inflows.
- Pharma Stock Pressure: Pharmaceutical stocks face downward pressure after the Centers for Medicare and Medicaid Services proposed new drug price negotiations, with analysts warning of potential risks for companies like Johnson & Johnson and Bristol Myers, impacting their short-term performance.
- Salesforce Acquisition: Salesforce announced its acquisition of customer service platform Fin for $3.6 billion, expected to close in Q4 of fiscal year 2027, aimed at enhancing its AI customer service capabilities, although its stock failed to maintain gains during the market rally, highlighting uncertainty about AI's long-term impact.
See More
CMS Proposes Permanent Drug Price Negotiations for Medicare
- Negotiation Risk: The CMS proposed rule unveiled on June 12 aims to make Medicare drug price negotiations permanent, set to take effect in 2029, which has led to a decline in stock prices for drugmakers like Merck (MRK), Johnson & Johnson (JNJ), and Bristol Myers Squibb (BMY) due to increased negotiation risk.
- Market Impact: RBC analyst Trung Huynh warned that this development places significant pressure on pharmaceutical companies, particularly those relying on drugs like Darzalex, Opdivo, and Keytruda to extend their product lifecycles, potentially affecting their future revenue forecasts.
- Biosimilar Protection: In contrast, Regeneron's Eylea HD remains protected from this negotiation risk due to the existence of bona fide marketed biosimilars, exempting its entire product bundle from the proposed rule, which may help maintain its competitive edge in the market.
- Clinical Trial Results: Johnson & Johnson's multiple myeloma drug Talvey has shown a mortality risk reduction of up to 53% in late-stage trials, which may alleviate some investor concerns regarding the implications of the CMS proposal.
See More
